Drug Trial Radar · NCT02144077
Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy
Last checked: Nov 20, 2026Latest source record: Nov 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
281
Actual
Start
Jan 28, 2014
Primary completion
Nov 17, 2015
Study completion Sep 9, 2020
Sponsor
- Lead sponsor
- Biofrontera Bioscience GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Accovion GmbH
- First posted
- May 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).
Conditions
- Basal Cell Carcinoma (BCC)
Interventions
BF-200 ALADrug
Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
methyl-aminolevulinateDrug
Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDTTime frame: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Klinikum Vest GmbH
Recklinghausen, Westfalen-Lippe, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.